Brief: Blueprint Medicines Announces Lift Of Partial Clinical Hold On Phase 1/2 Vela Trial Of Blu-222
28/03/2023 21:28
March 28 (Reuters) - Blueprint Medicines Corp BPMC.O :
* BLUEPRINT MEDICINES ANNOUNCES LIFT OF PARTIAL CLINICAL
HOLD ON
PHASE 1/2 VELA TRIAL OF BLU-222
* BLUEPRINT MEDICINES CORP - LOOK FORWARD TO PRESENTING
INITIAL
DOSE ESCALATION DATA FROM VELA TRIAL IN Q2 OF 2023
* BLUEPRINT MEDICINES CORP - BLUEPRINT MEDICINES IS WORKING
WITH
TRIAL SITES TO REINITIATE PATIENT ENROLLMENT
Source text for Eikon: ID:nPn6JHF3Ba
Further company coverage: BPMC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Blueprint Medicines
See all newsBrief: Sanofi Announces Extension Of Blueprint Tender Offer
Brief: Blueprint Medicines Announces Data Reinforcing Safety Profile Of Long-Term Ayvakit
U.S. STOCKS ON THE MOVE-Texas Instruments, Broadcom, Circle
UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal
U.S. RESEARCH ROUNDUP-Biomea Fusion, GE Aerospace, P&G